Pharma major Novartis falls 9% after three drug trial setbacks
CNBC
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC